Skip to main content
Premium Trial:

Request an Annual Quote

FedMed to Cover BioTheranostics Cancer MDx Tests

NEW YORK (GenomeWeb) – Genomic cancer diagnostic firm BioTheranostics today announced a contract with preferred provider organization FedMed to cover its tests for breast cancer and metastatic cancers.

As a result of the agreement, FedMed's 40 million covered lives will have access to San Diego-based BioTheranostics tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, as well as the BioT3 Metastatic Cancer Solution suite of tests, which provides diagnostic and therapeutic information for metastatic cancer patients.

The BioT3 Metastatic Cancer Solution tests include the CancerType ID molecular classifier for diagnosing tumor type and subtype, and the CancerTreatment ID, which uses next-generation sequencing and predictive biomarkers to identify appropriate treatment options.

Today's announcement is the latest in a string of agreements that BioTheranostics has recently reached with PPOs, including Prime Health Services and Three Rivers Provider Network.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.